数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Thomas Woiwode Director 48 46.81万美元 未持股 2020-04-15
Leone Patterson Director,President and Chief Executive Officer 57 283.03万美元 未持股 2020-04-15
Rekha Hemrajani Director 50 79.10万美元 未持股 2020-04-15
Mark Lupher Director 49 78.57万美元 未持股 2020-04-15
C. Patrick Machado Chair of the Board 56 50.40万美元 未持股 2020-04-15
Scott M. Whitcup Director 60 未披露 未持股 2020-04-15
Eric G. Carter Director 68 47.86万美元 未持股 2020-04-15
James Scopa Director 61 78.98万美元 未持股 2020-04-15
Mehdi Gasmi Director 53 10.64万美元 未持股 2020-04-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Leone Patterson Director,President and Chief Executive Officer 57 283.03万美元 未持股 2020-04-15
Thomas Leung Chief Financial Officer 39 243.54万美元 未持股 2020-04-15
Aaron Osborne Chief Medical Officer 46 238.22万美元 未持股 2020-04-15
Peter Soparkar Chief Legal Officer 49 未披露 未持股 2020-04-15
Angela Thedinga Chief Technology Officer 38 未披露 未持股 2020-04-15
C. Patrick Machado Chair of the Board 56 50.40万美元 未持股 2020-04-15

董事简历

中英对照 |  中文 |  英文
Thomas Woiwode

Thomas Woiwode,从2013年7月起担任我们董事会成员。Woiwode 博士2002年起在Versant Ventures担任不同的职位,2011年起担任投资合伙人;2014年7月起担任总经理。他曾在这段时间里担任许多运营职位,最近担任Okairos首席运营官。Woiwode 博士还在Versant Ventures联合创立了一家独资生物技术孵化器,为三个在Versant创立的生物技术公司担任创始首席商务官。他还曾在XenoPort, Inc.担任演技科学家;他还在数个私有企业董事会任职。Woiwode博士持有California 大学Berkeley 分校的文学士和理学位以及斯坦福大学的博士学位。


Thomas Woiwode has served as the chairman of our board of directors since May 2019. Dr. Woiwode has been with Versant Venture Management, LLC, or Versant Ventures, a healthcare investment firm, since 2002 in various capacities, serving as a managing director since July 2014 and previously as a venture partner from June 2011 to July 2014. He has also served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, or Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases, from April 2011 until May 2013. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotechnology companies created within Versant Ventures. Before joining Versant Ventures, Dr. Woiwode also served as a research scientist at XenoPort, Inc. Dr. Woiwode serves on the board of directors of several private companies and on the board of directors of four public companies, Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., Gritstone Oncology, Inc and Passage BIO, Inc. and served on the board of directors of Audentes Therapeutics, Inc. from July 2013 to July 2017 and CRISPR Therapeutics AG from April 2014 to June 2019. Dr. Woiwode holds a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry as an NSF Fellow from Stanford University.
Thomas Woiwode,从2013年7月起担任我们董事会成员。Woiwode 博士2002年起在Versant Ventures担任不同的职位,2011年起担任投资合伙人;2014年7月起担任总经理。他曾在这段时间里担任许多运营职位,最近担任Okairos首席运营官。Woiwode 博士还在Versant Ventures联合创立了一家独资生物技术孵化器,为三个在Versant创立的生物技术公司担任创始首席商务官。他还曾在XenoPort, Inc.担任演技科学家;他还在数个私有企业董事会任职。Woiwode博士持有California 大学Berkeley 分校的文学士和理学位以及斯坦福大学的博士学位。
Thomas Woiwode has served as the chairman of our board of directors since May 2019. Dr. Woiwode has been with Versant Venture Management, LLC, or Versant Ventures, a healthcare investment firm, since 2002 in various capacities, serving as a managing director since July 2014 and previously as a venture partner from June 2011 to July 2014. He has also served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, or Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases, from April 2011 until May 2013. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotechnology incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotechnology companies created within Versant Ventures. Before joining Versant Ventures, Dr. Woiwode also served as a research scientist at XenoPort, Inc. Dr. Woiwode serves on the board of directors of several private companies and on the board of directors of four public companies, Adverum Biotechnologies, Inc., Aligos Therapeutics, Inc., Gritstone Oncology, Inc and Passage BIO, Inc. and served on the board of directors of Audentes Therapeutics, Inc. from July 2013 to July 2017 and CRISPR Therapeutics AG from April 2014 to June 2019. Dr. Woiwode holds a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry as an NSF Fellow from Stanford University.
Leone Patterson

Leone Patterson于2018年10月被任命为我们的首席执行官。关于她的晋升,我们的董事会任命她为董事会成员。Patterson女士自2018年5月起担任临时总裁兼首席执行官,并于2018年10月至2019年12月担任我们的总裁。她还于2016年6月至2019年4月担任我们的首席财务官。2015年3月至2016年6月,帕特森女士担任诊断公司Diadexus,Inc.的首席财务官,负责监督该公司的财务职能。在此之前,帕特森从2012年6月起担任生物制药公司Transcept Pharmaceuticals,Inc.的Vice President和首席财务官,直到2014年10月该公司被Paratek Pharmaceuticals Inc.收购,她负责监管该公司的财务职能。Patterson女士从2010年11月到2012年6月担任NetApp,Inc.(一家数据管理和存储公司)的Vice President和全球公司财务总监。Patterson从2007年7月到2010年11月担任Exelixis,Inc(一家生物制药公司)金融Vice President。在Exelixis之前,Patterson女士从2006年4月到2007年7月担任生物制药公司Novartis AG疫苗和诊断部门全球业务规划和分析的Vice President。从1999年到2006年,她曾担任Chiron公司(生物技术公司,现为Novartis AG公司的一部分)的多种职务,包括Vice President、公司总会计师。从1989年到1999年,她曾任职会计师事务所KPMG的审计实践,在那里她曾担任多种职务,包括高级经理。Patterson女士目前在Nkarta,Inc.董事会任职。Patterson女士在查普曼大学(Chapman University)获得工商管理与会计学学士学位,并在圣玛丽学院(St.Mary’;s College)获得执行工商管理硕士学位。Patterson女士也是一名注册会计师(非活跃状态)。


Leone Patterson has been a member of our board of directors since March 2021. Ms. Patterson currently serves as Chief Financial and Business Officer of Tenaya Therapeutics, Inc., where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. Ms. Patterson joined Tenaya in June 2021. Prior to joining Tenaya, Ms. Patterson served as President and Chief Financial Officer of Adverum Biotechnologies, Inc., a public clinical-stage gene therapy company. Ms. Patterson joined Adverum in June 2016 as Chief Financial Officer and served as Chief Executive Officer from May 2018 to June 2020 Director from October 2018 to June 2020 and President from December 2019 to June 2021. From 2015 to 2016 Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc., a diagnostics company. Prior to that, Ms. Patterson was Vice President and Chief Financial Officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until it was acquired by Paratek Pharmaceuticals Inc. 2014. From 2010 to 2012 Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc., a data management and storage company. From 2007 to 2010 Ms. Patterson was Vice President of Finance at Exelixis. Before Exelixis, Ms. Patterson served as Vice President of Global Business Planning and Analysis of the vaccines and diagnostics division of Novartis AG, a biopharmaceutical company, from 2006 to 2007. From 1999 to 2006 she held several positions, including Vice President, Corporate Controller, at Chiron, a biotechnology company now part of Novartis AG. From 1989 to 1999 Ms. Patterson worked in the audit practice of accounting firm KPMG, where she held various positions including Senior Manager. Ms. Patterson currently serves on the board of directors of Nkarta, Inc. Ms. Patterson holds a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Leone Patterson于2018年10月被任命为我们的首席执行官。关于她的晋升,我们的董事会任命她为董事会成员。Patterson女士自2018年5月起担任临时总裁兼首席执行官,并于2018年10月至2019年12月担任我们的总裁。她还于2016年6月至2019年4月担任我们的首席财务官。2015年3月至2016年6月,帕特森女士担任诊断公司Diadexus,Inc.的首席财务官,负责监督该公司的财务职能。在此之前,帕特森从2012年6月起担任生物制药公司Transcept Pharmaceuticals,Inc.的Vice President和首席财务官,直到2014年10月该公司被Paratek Pharmaceuticals Inc.收购,她负责监管该公司的财务职能。Patterson女士从2010年11月到2012年6月担任NetApp,Inc.(一家数据管理和存储公司)的Vice President和全球公司财务总监。Patterson从2007年7月到2010年11月担任Exelixis,Inc(一家生物制药公司)金融Vice President。在Exelixis之前,Patterson女士从2006年4月到2007年7月担任生物制药公司Novartis AG疫苗和诊断部门全球业务规划和分析的Vice President。从1999年到2006年,她曾担任Chiron公司(生物技术公司,现为Novartis AG公司的一部分)的多种职务,包括Vice President、公司总会计师。从1989年到1999年,她曾任职会计师事务所KPMG的审计实践,在那里她曾担任多种职务,包括高级经理。Patterson女士目前在Nkarta,Inc.董事会任职。Patterson女士在查普曼大学(Chapman University)获得工商管理与会计学学士学位,并在圣玛丽学院(St.Mary’;s College)获得执行工商管理硕士学位。Patterson女士也是一名注册会计师(非活跃状态)。
Leone Patterson has been a member of our board of directors since March 2021. Ms. Patterson currently serves as Chief Financial and Business Officer of Tenaya Therapeutics, Inc., where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. Ms. Patterson joined Tenaya in June 2021. Prior to joining Tenaya, Ms. Patterson served as President and Chief Financial Officer of Adverum Biotechnologies, Inc., a public clinical-stage gene therapy company. Ms. Patterson joined Adverum in June 2016 as Chief Financial Officer and served as Chief Executive Officer from May 2018 to June 2020 Director from October 2018 to June 2020 and President from December 2019 to June 2021. From 2015 to 2016 Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc., a diagnostics company. Prior to that, Ms. Patterson was Vice President and Chief Financial Officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until it was acquired by Paratek Pharmaceuticals Inc. 2014. From 2010 to 2012 Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc., a data management and storage company. From 2007 to 2010 Ms. Patterson was Vice President of Finance at Exelixis. Before Exelixis, Ms. Patterson served as Vice President of Global Business Planning and Analysis of the vaccines and diagnostics division of Novartis AG, a biopharmaceutical company, from 2006 to 2007. From 1999 to 2006 she held several positions, including Vice President, Corporate Controller, at Chiron, a biotechnology company now part of Novartis AG. From 1989 to 1999 Ms. Patterson worked in the audit practice of accounting firm KPMG, where she held various positions including Senior Manager. Ms. Patterson currently serves on the board of directors of Nkarta, Inc. Ms. Patterson holds a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Rekha Hemrajani

Rekha Hemrajani自2020年8月成立以来一直担任我们的首席执行官,并担任我们的董事会成员。Hemrajani女士是一位经验丰富的战略领导者,帮助生物技术公司进行企业战略和企业融资,以及通过企业发展建立产品管道。她在公共和私人生物制药公司、Bulge Bracket投资银行拥有丰富的高级管理经验。Hemrajani女士最近担任Aravive,Inc.的总裁兼首席执行官纳斯达克:ARAV,2020年1月至2020年4月。Hemrajani女士曾于2019年担任Arcus Biosciences的首席财务官兼首席运营官,领导财务,投资者关系,企业沟通,业务和企业发展,战略规划和人力资源。在加入Arcus之前,Hemrajani女士于2016年至2019年担任Rapt Therapeutics(纳斯达克股票代码:RAPT)的首席运营官,2014年期间担任Sagimet Biosciences的首席财务官,担任生物制药公司和投资基金的顾问,担任Onyx Pharmaceuticals(NASDAQ:ONXX,2012-2013年被Amgen以104亿美元收购),2003-2011年担任Exelixis(NASDAQ:EXEL)业务开发副总裁。Hemrajani女士目前是ALX Oncology(纳斯达克市场代码:ALXO)和Adverum Biotechnologies(纳斯达克市场代码:ADVM)的董事。Hemrajani女士拥有西北大学凯洛格管理学院(Kellogg School of Management at Northwestern University)工商管理硕士学位和密歇根大学(University of Michigan)理学学士学位。


Rekha Hemrajani has served on our Board since June 2021. Ms. Hemrajani has served as Chief Executive Officer and Director of Jiya Acquisition Corporation since August 2020. She previously served as President and Chief Executive Officer of Aravive, Inc., a clinical-stage biotechnology company, from January 2020 to April 2020. From March 2019 to September 2019 Ms. Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From March 2016 to March 2019 she served as Chief Operating Officer of FLX Bio, Inc. now RAPT Therapeutics, Inc., a biotechnology company. Ms. Hemrajani currently serves as a director of the publicly held company ALX Oncology Holdings, Inc. and previously served as a director of Adverum Biotechnologies, Inc. and Aravive, Inc. She holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Rekha Hemrajani自2020年8月成立以来一直担任我们的首席执行官,并担任我们的董事会成员。Hemrajani女士是一位经验丰富的战略领导者,帮助生物技术公司进行企业战略和企业融资,以及通过企业发展建立产品管道。她在公共和私人生物制药公司、Bulge Bracket投资银行拥有丰富的高级管理经验。Hemrajani女士最近担任Aravive,Inc.的总裁兼首席执行官纳斯达克:ARAV,2020年1月至2020年4月。Hemrajani女士曾于2019年担任Arcus Biosciences的首席财务官兼首席运营官,领导财务,投资者关系,企业沟通,业务和企业发展,战略规划和人力资源。在加入Arcus之前,Hemrajani女士于2016年至2019年担任Rapt Therapeutics(纳斯达克股票代码:RAPT)的首席运营官,2014年期间担任Sagimet Biosciences的首席财务官,担任生物制药公司和投资基金的顾问,担任Onyx Pharmaceuticals(NASDAQ:ONXX,2012-2013年被Amgen以104亿美元收购),2003-2011年担任Exelixis(NASDAQ:EXEL)业务开发副总裁。Hemrajani女士目前是ALX Oncology(纳斯达克市场代码:ALXO)和Adverum Biotechnologies(纳斯达克市场代码:ADVM)的董事。Hemrajani女士拥有西北大学凯洛格管理学院(Kellogg School of Management at Northwestern University)工商管理硕士学位和密歇根大学(University of Michigan)理学学士学位。
Rekha Hemrajani has served on our Board since June 2021. Ms. Hemrajani has served as Chief Executive Officer and Director of Jiya Acquisition Corporation since August 2020. She previously served as President and Chief Executive Officer of Aravive, Inc., a clinical-stage biotechnology company, from January 2020 to April 2020. From March 2019 to September 2019 Ms. Hemrajani served as the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company. From March 2016 to March 2019 she served as Chief Operating Officer of FLX Bio, Inc. now RAPT Therapeutics, Inc., a biotechnology company. Ms. Hemrajani currently serves as a director of the publicly held company ALX Oncology Holdings, Inc. and previously served as a director of Adverum Biotechnologies, Inc. and Aravive, Inc. She holds a B.S. in Economics and Computer Science from the University of Michigan and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
Mark Lupher

Mark Lupher自2016年3月起担任SutroBiopharma,Inc.(一家公开上市的药物发现,开发和制造公司)转化药理学和临床前开发Vice President。Lupher博士于2013年6月创立了VeritasRx Consulting,这是一家咨询公司,自那时起,他一直担任其总裁,为风险投资公司和生物制药公司提供咨询,包括2014年5月至2016年3月的SutroBiopharma,Inc.。在加入VeritasRx之前,Lupher博士曾在ProMedior,Inc.担任多个职位,2010年6月至2013年6月担任首席科学官,2009年6月至2010年6月担任高级副总裁,Discovery Research,2007年2月至2009年6月担任药物发现Vice President。加入ProMedior之前,Lupher从1998年10月到2007年2月在ICOS Corporation担任多个职位。Lupher博士在哈佛大学(Harvard University)获得免疫学博士学位,在华盛顿大学(University of Washington)获得微生物学学士学位。


Mark Lupher has served as vice president of translational pharmacology and preclinical development at Sutro Biopharma, Inc., a publicly traded drug discovery, development and manufacturing company, since March 2016. In June 2013 Dr. Lupher founded VeritasRx Consulting, a consulting firm, and he has served as its president since that time, consulting for venture capital firms and biopharmaceutical companies, including Sutro Biopharma, Inc. from May 2014 to March 2016. Prior to VeritasRx, Dr. Lupher held various roles with Promedior, Inc., where he served as chief scientific officer from June 2010 to June 2013 as senior vice president, discovery research from June 2009 to June 2010 and as vice president, drug discovery from February 2007 to June 2009. Prior to Promedior, Dr. Lupher held various roles with ICOS Corporation from October 1998 to February 2007. Dr. Lupher received a Ph.D. in immunology from Harvard University and a B.S. in microbiology from the University of Washington.
Mark Lupher自2016年3月起担任SutroBiopharma,Inc.(一家公开上市的药物发现,开发和制造公司)转化药理学和临床前开发Vice President。Lupher博士于2013年6月创立了VeritasRx Consulting,这是一家咨询公司,自那时起,他一直担任其总裁,为风险投资公司和生物制药公司提供咨询,包括2014年5月至2016年3月的SutroBiopharma,Inc.。在加入VeritasRx之前,Lupher博士曾在ProMedior,Inc.担任多个职位,2010年6月至2013年6月担任首席科学官,2009年6月至2010年6月担任高级副总裁,Discovery Research,2007年2月至2009年6月担任药物发现Vice President。加入ProMedior之前,Lupher从1998年10月到2007年2月在ICOS Corporation担任多个职位。Lupher博士在哈佛大学(Harvard University)获得免疫学博士学位,在华盛顿大学(University of Washington)获得微生物学学士学位。
Mark Lupher has served as vice president of translational pharmacology and preclinical development at Sutro Biopharma, Inc., a publicly traded drug discovery, development and manufacturing company, since March 2016. In June 2013 Dr. Lupher founded VeritasRx Consulting, a consulting firm, and he has served as its president since that time, consulting for venture capital firms and biopharmaceutical companies, including Sutro Biopharma, Inc. from May 2014 to March 2016. Prior to VeritasRx, Dr. Lupher held various roles with Promedior, Inc., where he served as chief scientific officer from June 2010 to June 2013 as senior vice president, discovery research from June 2009 to June 2010 and as vice president, drug discovery from February 2007 to June 2009. Prior to Promedior, Dr. Lupher held various roles with ICOS Corporation from October 1998 to February 2007. Dr. Lupher received a Ph.D. in immunology from Harvard University and a B.S. in microbiology from the University of Washington.
C. Patrick Machado

C. Patrick Machado,从2004年12月开始,他担任公司首席财务官,直到2014年3月,将该职位转换给Mr. Rick Bierly ;从2009年12月到2014年4月他退休期间,他担任首席业务官。之前,从公司2003年9月创立到2004年12月该公司通过合并成为我们公司的全资子公司期间,他在Medivation Neurology担任高级副总裁、首席财务官和董事。从1998年到2001年,他在ProDuct Health公司任职,这是一家私人医疗器材公司,从1998年到2000年,他担任副总裁、首席财务官和总经理;从2000年到2001年他担任高级副总裁和首席财务官。从2001年到2002年,他在Cytyc 公司担任咨询师,帮助该公司收购ProDuct Health 公司的交易事务。他在哈佛大学法学院(Harvard Law School)得到法律博士学位,在圣克拉拉大学(Santa Clara University)得到法语和经济学双学士学位。


C. Patrick Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from 2009 to 2014 and as its chief financial officer from 2004 until his retirement in 2014. From 1998 to 2001 Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as a member of the board of directors of Arcus Biosciences, Inc., Chimerix, Inc., Turning Point Therapeutics, Inc., Principia Biopharma Inc., and several private companies, and previously served on the board of directors of Endocyte, Inc., Inotek Pharmaceuticals Corporation now Rocket Pharmaceuticals, Inc., Axovant Sciences, Inc. Medivation, Inc. and SCYNEXIS, Inc. Mr. Machado received a B.A. in German and a B.S. in Economics from Santa Clara University and a J.D. from Harvard Law School.
C. Patrick Machado,从2004年12月开始,他担任公司首席财务官,直到2014年3月,将该职位转换给Mr. Rick Bierly ;从2009年12月到2014年4月他退休期间,他担任首席业务官。之前,从公司2003年9月创立到2004年12月该公司通过合并成为我们公司的全资子公司期间,他在Medivation Neurology担任高级副总裁、首席财务官和董事。从1998年到2001年,他在ProDuct Health公司任职,这是一家私人医疗器材公司,从1998年到2000年,他担任副总裁、首席财务官和总经理;从2000年到2001年他担任高级副总裁和首席财务官。从2001年到2002年,他在Cytyc 公司担任咨询师,帮助该公司收购ProDuct Health 公司的交易事务。他在哈佛大学法学院(Harvard Law School)得到法律博士学位,在圣克拉拉大学(Santa Clara University)得到法语和经济学双学士学位。
C. Patrick Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from 2009 to 2014 and as its chief financial officer from 2004 until his retirement in 2014. From 1998 to 2001 Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as a member of the board of directors of Arcus Biosciences, Inc., Chimerix, Inc., Turning Point Therapeutics, Inc., Principia Biopharma Inc., and several private companies, and previously served on the board of directors of Endocyte, Inc., Inotek Pharmaceuticals Corporation now Rocket Pharmaceuticals, Inc., Axovant Sciences, Inc. Medivation, Inc. and SCYNEXIS, Inc. Mr. Machado received a B.A. in German and a B.S. in Economics from Santa Clara University and a J.D. from Harvard Law School.
Scott M. Whitcup

Scott M. Whitcup, 自2009年4月一直担任研发执行副总裁兼首席科学官。在此之前,自2004年7月,担任研发执行副总裁。 2000年1月,他加入Allergan,担任副总裁,负责。2004年1月他成为Allergan公司的高级副总裁,负责眼科发展。从1993年到2000年,他曾担任美国国立卫生研究院的美国国家眼科研究所的临床主任。作为临床主任,在建设临床研究计划,并倡导新的眼科治疗的发现方面他的领导是至关重要的。 同时他是朱尔斯·斯坦眼科研究所/大卫格芬医学院在加州大学洛杉矶分校的一名教师。 他还是公开上市的生物制药公司QUESTCOR制药公司和私人持有的公司Semnur制药的董事会成员。


Scott M. Whitcup is the founder and chief executive officer of two companies focused on developing new therapies in ophthalmology and dermatology, Akrivista LLC and Whitecap Biosciences LLC, positions he has held since October 2015 and November 2015 respectively. He has also served on the clinical faculty at the UCLA Stein Eye Institute since July 2003. Previously, Dr. Whitcup served in a number of positions at Allergan, Inc., most recently as the executive vice president of research and development and chief scientific officer, from April 2009 to March 2015. Earlier in his career, Dr. Whitcup was the clinical director at the National Eye Institute at the National Institutes of Health. He previously served on the boards of Menlo Therapeutics Inc., a biopharmaceutical company, and Nightstar Therapeutics plc, a gene therapy company and currently serves on a number of private company boards. Dr. Whitcup earned a B.A. from Cornell University and an M.D. from Cornell University Medical College. He completed an internal medicine residency at UCLA and an ophthalmology residency at Harvard University at the Massachusetts Eye and Ear Infirmary.
Scott M. Whitcup, 自2009年4月一直担任研发执行副总裁兼首席科学官。在此之前,自2004年7月,担任研发执行副总裁。 2000年1月,他加入Allergan,担任副总裁,负责。2004年1月他成为Allergan公司的高级副总裁,负责眼科发展。从1993年到2000年,他曾担任美国国立卫生研究院的美国国家眼科研究所的临床主任。作为临床主任,在建设临床研究计划,并倡导新的眼科治疗的发现方面他的领导是至关重要的。 同时他是朱尔斯·斯坦眼科研究所/大卫格芬医学院在加州大学洛杉矶分校的一名教师。 他还是公开上市的生物制药公司QUESTCOR制药公司和私人持有的公司Semnur制药的董事会成员。
Scott M. Whitcup is the founder and chief executive officer of two companies focused on developing new therapies in ophthalmology and dermatology, Akrivista LLC and Whitecap Biosciences LLC, positions he has held since October 2015 and November 2015 respectively. He has also served on the clinical faculty at the UCLA Stein Eye Institute since July 2003. Previously, Dr. Whitcup served in a number of positions at Allergan, Inc., most recently as the executive vice president of research and development and chief scientific officer, from April 2009 to March 2015. Earlier in his career, Dr. Whitcup was the clinical director at the National Eye Institute at the National Institutes of Health. He previously served on the boards of Menlo Therapeutics Inc., a biopharmaceutical company, and Nightstar Therapeutics plc, a gene therapy company and currently serves on a number of private company boards. Dr. Whitcup earned a B.A. from Cornell University and an M.D. from Cornell University Medical College. He completed an internal medicine residency at UCLA and an ophthalmology residency at Harvard University at the Massachusetts Eye and Ear Infirmary.
Eric G. Carter

Eric G. Carter于2018年4月至2019年1月担任生物制药公司Alder Biopharmaceuticals, Inc.的临时首席医疗官。Carter博士曾担任制药公司Allergan plc的高级副总裁、首席医疗官和临床和非临床开发全球负责人,从2011年到2015年被Actavis Pharmaceuticals收购之前,该公司一直处于显着增长时期。在加入Allergan之前,Carter博士从2007年起担任King Pharmaceuticals的首席科学官、研发主管和首席医疗官,直到该公司于2011年被辉瑞公司收购。从2001年到2007年,他在制药公司GlaxoSmithKline plc工作,在全球临床开发和医疗事务领域担任越来越多的职务。在北卡罗来纳大学医学院、加州大学洛杉矶分校菲尔丁公共卫生学院和加州大学伯克利分校的学术界任职后,卡特博士于1993年在制药公司Pharmacia Corporation开始了他的制药职业生涯。他获得了学士学位。伦敦大学生物化学博士,博士剑桥大学生物化学博士,迈阿密大学医学院医学博士。Carter博士目前担任Bioniz Therapeutics科学顾问委员会主席。


Eric G. Carter served as Interim Chief Medical Officer of Alder BioPharmaceuticals, Inc., a biopharmaceuticals company, from April 2018 to January 2019. Dr. Carter served as senior vice president, chief medical officer, and global head of clinical and non-clinical development of Allergan plc, a pharmaceutical company, from 2011 through a period of significant growth until its acquisition by Actavis Pharmaceuticals in 2015. Prior to Allergan, Dr. Carter served as chief scientific officer, head of research and development, and chief medical officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer, Inc. in 2011. From 2001 to 2007 he worked for GlaxoSmithKline plc, a pharmaceutical company, in positions of increasing responsibility within the global clinical development and medical affairs areas. After serving in academia at the University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. He received a B.Sc. in Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine. Dr. Carter currently serves as the chair of the scientific advisory board at Bioniz Therapeutics.
Eric G. Carter于2018年4月至2019年1月担任生物制药公司Alder Biopharmaceuticals, Inc.的临时首席医疗官。Carter博士曾担任制药公司Allergan plc的高级副总裁、首席医疗官和临床和非临床开发全球负责人,从2011年到2015年被Actavis Pharmaceuticals收购之前,该公司一直处于显着增长时期。在加入Allergan之前,Carter博士从2007年起担任King Pharmaceuticals的首席科学官、研发主管和首席医疗官,直到该公司于2011年被辉瑞公司收购。从2001年到2007年,他在制药公司GlaxoSmithKline plc工作,在全球临床开发和医疗事务领域担任越来越多的职务。在北卡罗来纳大学医学院、加州大学洛杉矶分校菲尔丁公共卫生学院和加州大学伯克利分校的学术界任职后,卡特博士于1993年在制药公司Pharmacia Corporation开始了他的制药职业生涯。他获得了学士学位。伦敦大学生物化学博士,博士剑桥大学生物化学博士,迈阿密大学医学院医学博士。Carter博士目前担任Bioniz Therapeutics科学顾问委员会主席。
Eric G. Carter served as Interim Chief Medical Officer of Alder BioPharmaceuticals, Inc., a biopharmaceuticals company, from April 2018 to January 2019. Dr. Carter served as senior vice president, chief medical officer, and global head of clinical and non-clinical development of Allergan plc, a pharmaceutical company, from 2011 through a period of significant growth until its acquisition by Actavis Pharmaceuticals in 2015. Prior to Allergan, Dr. Carter served as chief scientific officer, head of research and development, and chief medical officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer, Inc. in 2011. From 2001 to 2007 he worked for GlaxoSmithKline plc, a pharmaceutical company, in positions of increasing responsibility within the global clinical development and medical affairs areas. After serving in academia at the University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. He received a B.Sc. in Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine. Dr. Carter currently serves as the chair of the scientific advisory board at Bioniz Therapeutics.
James Scopa

James Scopa ,他曾担任我们的董事会成员(2011年3月以来)。他担任MPM Capital旧金山的办公室的常务董事。他于2005年加入该公司。此前,他任职Deutsche Banc Alex和Brown and Thomas Weisel Partners的18年,提供成长型公司生物制药及医疗设备建议。他担任全球医疗保健投资银行业务的常务董事兼联席主管。任职Thomas Weisel Partners时,他曾任职医疗风险基金的投资委员会,并担任医疗保健投资银行董事。他拥有美国哈佛大学学士学位,是优等生荣誉学会成员,并获得哈佛商学院工商管理硕士学位和哈佛大学法学院法学博士学位。他目前任职Astute Medical、 iPierian, Solasia Pharma K.K、 TriVascular,并曾任职Peplin (出售给LEO Pharmaceuticals)的董事会。


James Scopa has been a member of the advisory board and the investment advisory committee of OneVentures, an Australian venture capital firm, since July 2017. From January 2017 to June 2018 he was a fellow at Stanford University in the Distinguished Careers Institute. From 2005 to 2016 Mr. Scopa served on the Investment Committee of MPM Capital, a life sciences venture capital firm, and was a Managing Director in MPM Capital’s San Francisco office from 2005 to 2017. Previously, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices at Deutsche Banc Alex. Brown and Thomas Weisel Partners. At Deutsche Banc Alex. Brown he served as Managing Director and Global Co-Head of Healthcare Investment Banking. He holds an A.B. from Harvard College, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School. Mr. Scopa also serves on the board of Blade Therapeutics, Inc. and has previously served on the boards of Semma Therapeutics, Inc. sold to Vertex Pharmaceuticals, Inc., True North Therapeutics, Inc. (sold to Bioverative Inc.), Conatus Pharmaceuticals Inc., Peplin Inc. (sold to LEO Pharma Inc.), Solasia Pharma K.K. and TriVascular Technologies, Inc. (sold to Endologix, Inc.).
James Scopa ,他曾担任我们的董事会成员(2011年3月以来)。他担任MPM Capital旧金山的办公室的常务董事。他于2005年加入该公司。此前,他任职Deutsche Banc Alex和Brown and Thomas Weisel Partners的18年,提供成长型公司生物制药及医疗设备建议。他担任全球医疗保健投资银行业务的常务董事兼联席主管。任职Thomas Weisel Partners时,他曾任职医疗风险基金的投资委员会,并担任医疗保健投资银行董事。他拥有美国哈佛大学学士学位,是优等生荣誉学会成员,并获得哈佛商学院工商管理硕士学位和哈佛大学法学院法学博士学位。他目前任职Astute Medical、 iPierian, Solasia Pharma K.K、 TriVascular,并曾任职Peplin (出售给LEO Pharmaceuticals)的董事会。
James Scopa has been a member of the advisory board and the investment advisory committee of OneVentures, an Australian venture capital firm, since July 2017. From January 2017 to June 2018 he was a fellow at Stanford University in the Distinguished Careers Institute. From 2005 to 2016 Mr. Scopa served on the Investment Committee of MPM Capital, a life sciences venture capital firm, and was a Managing Director in MPM Capital’s San Francisco office from 2005 to 2017. Previously, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices at Deutsche Banc Alex. Brown and Thomas Weisel Partners. At Deutsche Banc Alex. Brown he served as Managing Director and Global Co-Head of Healthcare Investment Banking. He holds an A.B. from Harvard College, an M.B.A. from Harvard Business School and a J.D. from Harvard Law School. Mr. Scopa also serves on the board of Blade Therapeutics, Inc. and has previously served on the boards of Semma Therapeutics, Inc. sold to Vertex Pharmaceuticals, Inc., True North Therapeutics, Inc. (sold to Bioverative Inc.), Conatus Pharmaceuticals Inc., Peplin Inc. (sold to LEO Pharma Inc.), Solasia Pharma K.K. and TriVascular Technologies, Inc. (sold to Endologix, Inc.).
Mehdi Gasmi

Mehdi Gasmi获得博士学位,Gasmi博士从2013年11月开始担任我司药物开发部的副总裁,并领导了我司候选基因疗法产品的制造与质量控制活动。在这之前,Gasmi博士负责Généthon的重组腺相关病毒与慢病毒基因疗法产品的临床批次的生产,这是一家基因疗法公司,从2009年7月到2011年12月,他在该公司担任生物制造部的副总裁,并负责Ceregene的重组腺相关病毒与慢病毒基因疗法产品的临床批次的生产,这是一家基因疗法公司,从2001年12月到2009年6月,Gasmi博士在该公司担任产品开发部的高级总监。Gasmi博士在法国里昂的克劳德贝尔纳大学(Claude Bernard University)获得生物化学理学硕士学位与博士学位。他是美国基因与细胞治疗学会(American Society of Gene and Cell Therapy)的会员。


Mehdi Gasmi is the principal of ClinVec Solutions, LLC, which provides adeno-associated virus “AAV” and lentiviral gene therapy consulting services. From September 2019 to March 2020 Dr. Gasmi, through ClinVec Solutions, LLC, provided such consulting services to us. Dr. Gasmi previously served as our president and chief scientific officer from October 2018 to September 2019. From February 2017 to October 2018 he served as our chief science and technology officer. Previously, he served as our interim chief scientific officer from July 2015 to February 2018 senior vice president, pharmaceutical development from May 2015 to July 2015 and as vice president, pharmaceutical development from November 2013 to May 2015. From December 2011 to November 2013 as principal of ClinVec Solutions, LLC, Dr. Gasmi provided AAV and lentiviral gene therapy consulting services to various companies, including to us. Prior to that, Dr. Gasmi oversaw production of clinical batches of recombinant AAV and lentiviral gene therapy products for both Genethon, a nonprofit gene therapy company, where he served as vice president of biomanufacturing from July 2009 to December 2011 and for Ceregene, a gene therapy company, where he served as senior director, product development from December 2001 to June 2009. Dr. Gasmi obtained his M.S. and his Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.
Mehdi Gasmi获得博士学位,Gasmi博士从2013年11月开始担任我司药物开发部的副总裁,并领导了我司候选基因疗法产品的制造与质量控制活动。在这之前,Gasmi博士负责Généthon的重组腺相关病毒与慢病毒基因疗法产品的临床批次的生产,这是一家基因疗法公司,从2009年7月到2011年12月,他在该公司担任生物制造部的副总裁,并负责Ceregene的重组腺相关病毒与慢病毒基因疗法产品的临床批次的生产,这是一家基因疗法公司,从2001年12月到2009年6月,Gasmi博士在该公司担任产品开发部的高级总监。Gasmi博士在法国里昂的克劳德贝尔纳大学(Claude Bernard University)获得生物化学理学硕士学位与博士学位。他是美国基因与细胞治疗学会(American Society of Gene and Cell Therapy)的会员。
Mehdi Gasmi is the principal of ClinVec Solutions, LLC, which provides adeno-associated virus “AAV” and lentiviral gene therapy consulting services. From September 2019 to March 2020 Dr. Gasmi, through ClinVec Solutions, LLC, provided such consulting services to us. Dr. Gasmi previously served as our president and chief scientific officer from October 2018 to September 2019. From February 2017 to October 2018 he served as our chief science and technology officer. Previously, he served as our interim chief scientific officer from July 2015 to February 2018 senior vice president, pharmaceutical development from May 2015 to July 2015 and as vice president, pharmaceutical development from November 2013 to May 2015. From December 2011 to November 2013 as principal of ClinVec Solutions, LLC, Dr. Gasmi provided AAV and lentiviral gene therapy consulting services to various companies, including to us. Prior to that, Dr. Gasmi oversaw production of clinical batches of recombinant AAV and lentiviral gene therapy products for both Genethon, a nonprofit gene therapy company, where he served as vice president of biomanufacturing from July 2009 to December 2011 and for Ceregene, a gene therapy company, where he served as senior director, product development from December 2001 to June 2009. Dr. Gasmi obtained his M.S. and his Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.

高管简历

中英对照 |  中文 |  英文
Leone Patterson

Leone Patterson于2018年10月被任命为我们的首席执行官。关于她的晋升,我们的董事会任命她为董事会成员。Patterson女士自2018年5月起担任临时总裁兼首席执行官,并于2018年10月至2019年12月担任我们的总裁。她还于2016年6月至2019年4月担任我们的首席财务官。2015年3月至2016年6月,帕特森女士担任诊断公司Diadexus,Inc.的首席财务官,负责监督该公司的财务职能。在此之前,帕特森从2012年6月起担任生物制药公司Transcept Pharmaceuticals,Inc.的Vice President和首席财务官,直到2014年10月该公司被Paratek Pharmaceuticals Inc.收购,她负责监管该公司的财务职能。Patterson女士从2010年11月到2012年6月担任NetApp,Inc.(一家数据管理和存储公司)的Vice President和全球公司财务总监。Patterson从2007年7月到2010年11月担任Exelixis,Inc(一家生物制药公司)金融Vice President。在Exelixis之前,Patterson女士从2006年4月到2007年7月担任生物制药公司Novartis AG疫苗和诊断部门全球业务规划和分析的Vice President。从1999年到2006年,她曾担任Chiron公司(生物技术公司,现为Novartis AG公司的一部分)的多种职务,包括Vice President、公司总会计师。从1989年到1999年,她曾任职会计师事务所KPMG的审计实践,在那里她曾担任多种职务,包括高级经理。Patterson女士目前在Nkarta,Inc.董事会任职。Patterson女士在查普曼大学(Chapman University)获得工商管理与会计学学士学位,并在圣玛丽学院(St.Mary’;s College)获得执行工商管理硕士学位。Patterson女士也是一名注册会计师(非活跃状态)。


Leone Patterson has been a member of our board of directors since March 2021. Ms. Patterson currently serves as Chief Financial and Business Officer of Tenaya Therapeutics, Inc., where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. Ms. Patterson joined Tenaya in June 2021. Prior to joining Tenaya, Ms. Patterson served as President and Chief Financial Officer of Adverum Biotechnologies, Inc., a public clinical-stage gene therapy company. Ms. Patterson joined Adverum in June 2016 as Chief Financial Officer and served as Chief Executive Officer from May 2018 to June 2020 Director from October 2018 to June 2020 and President from December 2019 to June 2021. From 2015 to 2016 Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc., a diagnostics company. Prior to that, Ms. Patterson was Vice President and Chief Financial Officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until it was acquired by Paratek Pharmaceuticals Inc. 2014. From 2010 to 2012 Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc., a data management and storage company. From 2007 to 2010 Ms. Patterson was Vice President of Finance at Exelixis. Before Exelixis, Ms. Patterson served as Vice President of Global Business Planning and Analysis of the vaccines and diagnostics division of Novartis AG, a biopharmaceutical company, from 2006 to 2007. From 1999 to 2006 she held several positions, including Vice President, Corporate Controller, at Chiron, a biotechnology company now part of Novartis AG. From 1989 to 1999 Ms. Patterson worked in the audit practice of accounting firm KPMG, where she held various positions including Senior Manager. Ms. Patterson currently serves on the board of directors of Nkarta, Inc. Ms. Patterson holds a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Leone Patterson于2018年10月被任命为我们的首席执行官。关于她的晋升,我们的董事会任命她为董事会成员。Patterson女士自2018年5月起担任临时总裁兼首席执行官,并于2018年10月至2019年12月担任我们的总裁。她还于2016年6月至2019年4月担任我们的首席财务官。2015年3月至2016年6月,帕特森女士担任诊断公司Diadexus,Inc.的首席财务官,负责监督该公司的财务职能。在此之前,帕特森从2012年6月起担任生物制药公司Transcept Pharmaceuticals,Inc.的Vice President和首席财务官,直到2014年10月该公司被Paratek Pharmaceuticals Inc.收购,她负责监管该公司的财务职能。Patterson女士从2010年11月到2012年6月担任NetApp,Inc.(一家数据管理和存储公司)的Vice President和全球公司财务总监。Patterson从2007年7月到2010年11月担任Exelixis,Inc(一家生物制药公司)金融Vice President。在Exelixis之前,Patterson女士从2006年4月到2007年7月担任生物制药公司Novartis AG疫苗和诊断部门全球业务规划和分析的Vice President。从1999年到2006年,她曾担任Chiron公司(生物技术公司,现为Novartis AG公司的一部分)的多种职务,包括Vice President、公司总会计师。从1989年到1999年,她曾任职会计师事务所KPMG的审计实践,在那里她曾担任多种职务,包括高级经理。Patterson女士目前在Nkarta,Inc.董事会任职。Patterson女士在查普曼大学(Chapman University)获得工商管理与会计学学士学位,并在圣玛丽学院(St.Mary’;s College)获得执行工商管理硕士学位。Patterson女士也是一名注册会计师(非活跃状态)。
Leone Patterson has been a member of our board of directors since March 2021. Ms. Patterson currently serves as Chief Financial and Business Officer of Tenaya Therapeutics, Inc., where she leads corporate finance, investor relations, corporate communications, strategy and business development, as well as other operational functions. Ms. Patterson joined Tenaya in June 2021. Prior to joining Tenaya, Ms. Patterson served as President and Chief Financial Officer of Adverum Biotechnologies, Inc., a public clinical-stage gene therapy company. Ms. Patterson joined Adverum in June 2016 as Chief Financial Officer and served as Chief Executive Officer from May 2018 to June 2020 Director from October 2018 to June 2020 and President from December 2019 to June 2021. From 2015 to 2016 Ms. Patterson served as the Chief Financial Officer of Diadexus, Inc., a diagnostics company. Prior to that, Ms. Patterson was Vice President and Chief Financial Officer of Transcept Pharmaceuticals, Inc., a biopharmaceutical company, from 2012 until it was acquired by Paratek Pharmaceuticals Inc. 2014. From 2010 to 2012 Ms. Patterson served as Vice President and Global Corporate Controller of NetApp, Inc., a data management and storage company. From 2007 to 2010 Ms. Patterson was Vice President of Finance at Exelixis. Before Exelixis, Ms. Patterson served as Vice President of Global Business Planning and Analysis of the vaccines and diagnostics division of Novartis AG, a biopharmaceutical company, from 2006 to 2007. From 1999 to 2006 she held several positions, including Vice President, Corporate Controller, at Chiron, a biotechnology company now part of Novartis AG. From 1989 to 1999 Ms. Patterson worked in the audit practice of accounting firm KPMG, where she held various positions including Senior Manager. Ms. Patterson currently serves on the board of directors of Nkarta, Inc. Ms. Patterson holds a B.S. in business administration and accounting from Chapman University and an executive M.B.A. from St. Mary’s College. Ms. Patterson is also a Certified Public Accountant (inactive status).
Thomas Leung

梁锦松自2019年4月起担任我们的首席财务官。在加入我们之前,梁先生于2013年8月至2019年4月担任基因筛选公司Counsyl,Inc.的业务运营Vice President,该公司被MyriadGenetics,Inc.收购,他在该公司担任财务,战略,计费运营和销售运营的领导职务。在加入Counsyl之前,梁先生曾担任TPG Capital在旧金山和香港的Vice President,负责寻找投资来源、执行收购和融资以及管理投资组合公司。梁伯韬的职业生涯始于摩根士丹利&Co.的投行业务。他持有哈佛商学院(Harvard Business School)的工商管理硕士学位,并获得耶鲁大学(Yale University)的经济学和生物医学工程学士学位。


Thomas Leung has served as our chief financial officer since April 2019. Prior to joining us, Mr. Leung served as vice president, business operations at Counsyl, Inc., a genetic screening company acquired by Myriad Genetics, Inc., where he held leadership roles in finance, strategy, billing operations and sales operations from August 2013 to April 2019. Prior to Counsyl, Mr. Leung served as a vice president of TPG Capital in San Francisco and Hong Kong, where he was responsible for sourcing investments, executing acquisitions and financings and managing portfolio companies. Mr. Leung began his career in investment banking at Morgan Stanley & Co. He holds an M.B.A. from Harvard Business School and received a B.S. in economics and biomedical engineering from Yale University.
梁锦松自2019年4月起担任我们的首席财务官。在加入我们之前,梁先生于2013年8月至2019年4月担任基因筛选公司Counsyl,Inc.的业务运营Vice President,该公司被MyriadGenetics,Inc.收购,他在该公司担任财务,战略,计费运营和销售运营的领导职务。在加入Counsyl之前,梁先生曾担任TPG Capital在旧金山和香港的Vice President,负责寻找投资来源、执行收购和融资以及管理投资组合公司。梁伯韬的职业生涯始于摩根士丹利&Co.的投行业务。他持有哈佛商学院(Harvard Business School)的工商管理硕士学位,并获得耶鲁大学(Yale University)的经济学和生物医学工程学士学位。
Thomas Leung has served as our chief financial officer since April 2019. Prior to joining us, Mr. Leung served as vice president, business operations at Counsyl, Inc., a genetic screening company acquired by Myriad Genetics, Inc., where he held leadership roles in finance, strategy, billing operations and sales operations from August 2013 to April 2019. Prior to Counsyl, Mr. Leung served as a vice president of TPG Capital in San Francisco and Hong Kong, where he was responsible for sourcing investments, executing acquisitions and financings and managing portfolio companies. Mr. Leung began his career in investment banking at Morgan Stanley & Co. He holds an M.B.A. from Harvard Business School and received a B.S. in economics and biomedical engineering from Yale University.
Aaron Osborne

Aaron Osborne自2019年4月起担任我们的首席医疗官。在加入Adverum之前,奥斯本博士自2018年9月起担任生物技术公司Genentech Inc.眼科产品开发的首席医疗总监,并于2015年9月至2018年8月担任高级医疗总监,他曾负责领导Faricimab公司的湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的临床开发计划,以及学术合作。从2013年8月到2015年5月,他曾担任Alcon Research公司(眼科护理公司)的制药特许经营主管,负责全球医疗事务,在那里他曾负责开发战略营销的Alcon品牌的全球医疗事务计划,以及Alcon Retina计划的医疗沟通。加入Alcon之前,Osborne从2012年12月到2013年8月担任Novartis Pharma AG眼科全球医疗事务主管,从2010年12月到2013年8月担任Novartis Pharma AG Lucentis全球品牌医疗总监。Osborne博士在诺丁汉皇后医疗中心(Queens Medical Center,Nottingham)接受眼科培训,并在伦敦大学学院(University College London)获得医学学士学位和外科MBBS学位。


Aaron Osborne has served as our chief medical officer since April 2019. Prior to joining Adverum, Dr. Osborne was principal medical director since September 2018 and senior medical director from September 2015 through August 2018 of Ophthalmology Product Development at Genentech Inc., a biotechnology company, where he was responsible for leading clinical development programs for faricimab in wet age-related macular degeneration and diabetic macular edema, and academic collaborations. From August 2013 through May 2015 Dr. Osborne was the pharmaceuticals franchise head, Global Medical Affairs for Alcon Research Ltd., an eye care company, where he was responsible for developing global medical affairs plans for strategic marketed Alcon brands and for medical communications around Alcon retina programs. Prior to Alcon, Dr. Osborne served as global medical affairs head, Ophthalmics, at Novartis Pharma AG from December 2012 to August 2013 and as global brand medical director, Lucentis, at Novartis Pharma AG from December 2010 to August 2013. Dr. Osborne trained in ophthalmology at Queens Medical Center, Nottingham, and earned his Bachelor of Medicine, Bachelor of Surgery MBBS degree at University College London.
Aaron Osborne自2019年4月起担任我们的首席医疗官。在加入Adverum之前,奥斯本博士自2018年9月起担任生物技术公司Genentech Inc.眼科产品开发的首席医疗总监,并于2015年9月至2018年8月担任高级医疗总监,他曾负责领导Faricimab公司的湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的临床开发计划,以及学术合作。从2013年8月到2015年5月,他曾担任Alcon Research公司(眼科护理公司)的制药特许经营主管,负责全球医疗事务,在那里他曾负责开发战略营销的Alcon品牌的全球医疗事务计划,以及Alcon Retina计划的医疗沟通。加入Alcon之前,Osborne从2012年12月到2013年8月担任Novartis Pharma AG眼科全球医疗事务主管,从2010年12月到2013年8月担任Novartis Pharma AG Lucentis全球品牌医疗总监。Osborne博士在诺丁汉皇后医疗中心(Queens Medical Center,Nottingham)接受眼科培训,并在伦敦大学学院(University College London)获得医学学士学位和外科MBBS学位。
Aaron Osborne has served as our chief medical officer since April 2019. Prior to joining Adverum, Dr. Osborne was principal medical director since September 2018 and senior medical director from September 2015 through August 2018 of Ophthalmology Product Development at Genentech Inc., a biotechnology company, where he was responsible for leading clinical development programs for faricimab in wet age-related macular degeneration and diabetic macular edema, and academic collaborations. From August 2013 through May 2015 Dr. Osborne was the pharmaceuticals franchise head, Global Medical Affairs for Alcon Research Ltd., an eye care company, where he was responsible for developing global medical affairs plans for strategic marketed Alcon brands and for medical communications around Alcon retina programs. Prior to Alcon, Dr. Osborne served as global medical affairs head, Ophthalmics, at Novartis Pharma AG from December 2012 to August 2013 and as global brand medical director, Lucentis, at Novartis Pharma AG from December 2010 to August 2013. Dr. Osborne trained in ophthalmology at Queens Medical Center, Nottingham, and earned his Bachelor of Medicine, Bachelor of Surgery MBBS degree at University College London.
Peter Soparkar

Peter Soparkar自2019年10月起担任我们的首席法律官。Soparkar先生曾于2016年7月至2018年9月担任Counsyl,Inc.的首席法务官,公司秘书,人力资源主管和合规主管,在那里他领导了对公司法律和人力资源需求,债务和股权融资,投资者互动,IPO准备的支持,和MyriadGenetics,Inc.的购置Soparkar先生于2006年11月至2016年7月担任Jazz Pharmaceuticals plc的副总法律顾问Vice President,在那里他领导了法律团队对公司运营和其他业务的支持,包括提供大量债务和股权融资以及四项里程碑式的交易。在加入Jazz Pharmaceuticals之前,Soparkar先生曾在伦敦和旧金山的Latham&Watkins工作,业务横跨国际和国内市场,以及私人和公共交易。他在纽约大学法学院(New York University School of Law)获得法学博士学位,在奥柏林学院(Oberlin College)获得经济学和政治学学士学位。


Peter Soparkar has served as our chief legal officer since October 2019. Mr. Soparkar was previously chief legal officer, corporate secretary, head of human resources, and head of compliance at Counsyl, Inc. from July 2016 to September 2018 where he led support for the company’s legal and human resources needs, debt and equity financings, investor interactions, IPO preparations, and acquisition by Myriad Genetics, Inc. From November 2006 to July 2016 Mr. Soparkar served as Vice President, Associate General Counsel at Jazz Pharmaceuticals plc, where he led the legal team’s support of company operations and other business matters, including delivering on numerous debt and equity financings and four landmark transactions. Prior to Jazz Pharmaceuticals, Mr. Soparkar worked at Latham & Watkins in London and San Francisco, with a practice spanning international and domestic markets, as well as private and public transactions. He received a J.D. from New York University School of Law and a B.A. in economics and politics from Oberlin College.
Peter Soparkar自2019年10月起担任我们的首席法律官。Soparkar先生曾于2016年7月至2018年9月担任Counsyl,Inc.的首席法务官,公司秘书,人力资源主管和合规主管,在那里他领导了对公司法律和人力资源需求,债务和股权融资,投资者互动,IPO准备的支持,和MyriadGenetics,Inc.的购置Soparkar先生于2006年11月至2016年7月担任Jazz Pharmaceuticals plc的副总法律顾问Vice President,在那里他领导了法律团队对公司运营和其他业务的支持,包括提供大量债务和股权融资以及四项里程碑式的交易。在加入Jazz Pharmaceuticals之前,Soparkar先生曾在伦敦和旧金山的Latham&Watkins工作,业务横跨国际和国内市场,以及私人和公共交易。他在纽约大学法学院(New York University School of Law)获得法学博士学位,在奥柏林学院(Oberlin College)获得经济学和政治学学士学位。
Peter Soparkar has served as our chief legal officer since October 2019. Mr. Soparkar was previously chief legal officer, corporate secretary, head of human resources, and head of compliance at Counsyl, Inc. from July 2016 to September 2018 where he led support for the company’s legal and human resources needs, debt and equity financings, investor interactions, IPO preparations, and acquisition by Myriad Genetics, Inc. From November 2006 to July 2016 Mr. Soparkar served as Vice President, Associate General Counsel at Jazz Pharmaceuticals plc, where he led the legal team’s support of company operations and other business matters, including delivering on numerous debt and equity financings and four landmark transactions. Prior to Jazz Pharmaceuticals, Mr. Soparkar worked at Latham & Watkins in London and San Francisco, with a practice spanning international and domestic markets, as well as private and public transactions. He received a J.D. from New York University School of Law and a B.A. in economics and politics from Oberlin College.
Angela Thedinga

Angela Thedinga于2020年2月被任命为首席技术官。她于2019年8月加入Adverum,担任项目管理Vice President。在加入Adverum之前,Thedinga女士首先于2015年10月至2018年7月担任项目管理和战略总监,然后于2018年7月至2019年6月担任基因治疗公司Avexis,Inc.(Novartis)的项目管理Vice President兼办公室主任。在Avexis,Thedinga女士帮助开发了早期制造策略,使Avexis能够将其早期AAV制造过程过渡到可扩展的商业制造过程。作为Avexis的办公室主任,Thedinga女士领导了公司范围内的全球同步监管提交和基因治疗产品的商业发布工作。Thedinga女士在麻省理工学院(Massachusetts Institute of Technology)获得化学工程硕士学位,在麻省理工学院斯隆管理学院(MIT Sloan School of Management)获得工商管理硕士学位,在北卡罗来纳大学教堂山分校(University of North Carolina at Chapel Hill)获得公共卫生硕士学位,以及the University of Wisconsin化学工程理学学士学位。


Angela Thedinga was appointed chief technology officer in February 2020. She joined Adverum in August 2019 as vice president, program management. Prior to joining Adverum, Ms. Thedinga served first as director, program management and strategy from October 2015 to July 2018 and then as vice president of program management and chief of staff, from July 2018 to June 2019 at AveXis, Inc., a gene therapy company acquired by Novartis in 2018. At AveXis, Ms. Thedinga helped develop the early manufacturing strategy which enabled AveXis to transition its early-stage AAV manufacturing process to a scalable commercial manufacturing process. As chief of staff at AveXis, Ms. Thedinga led the company-wide effort for the global simultaneous regulatory submissions and the commercial launch of a gene therapy product. Ms. Thedinga earned a Master’s degree in chemical engineering from the Massachusetts Institute of Technology, a Master of Business Administration from the MIT Sloan School of Management, a Master of Public Health from the University of North Carolina at Chapel Hill, and a Bachelor of Science in chemical engineering from the University of Wisconsin.
Angela Thedinga于2020年2月被任命为首席技术官。她于2019年8月加入Adverum,担任项目管理Vice President。在加入Adverum之前,Thedinga女士首先于2015年10月至2018年7月担任项目管理和战略总监,然后于2018年7月至2019年6月担任基因治疗公司Avexis,Inc.(Novartis)的项目管理Vice President兼办公室主任。在Avexis,Thedinga女士帮助开发了早期制造策略,使Avexis能够将其早期AAV制造过程过渡到可扩展的商业制造过程。作为Avexis的办公室主任,Thedinga女士领导了公司范围内的全球同步监管提交和基因治疗产品的商业发布工作。Thedinga女士在麻省理工学院(Massachusetts Institute of Technology)获得化学工程硕士学位,在麻省理工学院斯隆管理学院(MIT Sloan School of Management)获得工商管理硕士学位,在北卡罗来纳大学教堂山分校(University of North Carolina at Chapel Hill)获得公共卫生硕士学位,以及the University of Wisconsin化学工程理学学士学位。
Angela Thedinga was appointed chief technology officer in February 2020. She joined Adverum in August 2019 as vice president, program management. Prior to joining Adverum, Ms. Thedinga served first as director, program management and strategy from October 2015 to July 2018 and then as vice president of program management and chief of staff, from July 2018 to June 2019 at AveXis, Inc., a gene therapy company acquired by Novartis in 2018. At AveXis, Ms. Thedinga helped develop the early manufacturing strategy which enabled AveXis to transition its early-stage AAV manufacturing process to a scalable commercial manufacturing process. As chief of staff at AveXis, Ms. Thedinga led the company-wide effort for the global simultaneous regulatory submissions and the commercial launch of a gene therapy product. Ms. Thedinga earned a Master’s degree in chemical engineering from the Massachusetts Institute of Technology, a Master of Business Administration from the MIT Sloan School of Management, a Master of Public Health from the University of North Carolina at Chapel Hill, and a Bachelor of Science in chemical engineering from the University of Wisconsin.
C. Patrick Machado

C. Patrick Machado,从2004年12月开始,他担任公司首席财务官,直到2014年3月,将该职位转换给Mr. Rick Bierly ;从2009年12月到2014年4月他退休期间,他担任首席业务官。之前,从公司2003年9月创立到2004年12月该公司通过合并成为我们公司的全资子公司期间,他在Medivation Neurology担任高级副总裁、首席财务官和董事。从1998年到2001年,他在ProDuct Health公司任职,这是一家私人医疗器材公司,从1998年到2000年,他担任副总裁、首席财务官和总经理;从2000年到2001年他担任高级副总裁和首席财务官。从2001年到2002年,他在Cytyc 公司担任咨询师,帮助该公司收购ProDuct Health 公司的交易事务。他在哈佛大学法学院(Harvard Law School)得到法律博士学位,在圣克拉拉大学(Santa Clara University)得到法语和经济学双学士学位。


C. Patrick Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from 2009 to 2014 and as its chief financial officer from 2004 until his retirement in 2014. From 1998 to 2001 Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as a member of the board of directors of Arcus Biosciences, Inc., Chimerix, Inc., Turning Point Therapeutics, Inc., Principia Biopharma Inc., and several private companies, and previously served on the board of directors of Endocyte, Inc., Inotek Pharmaceuticals Corporation now Rocket Pharmaceuticals, Inc., Axovant Sciences, Inc. Medivation, Inc. and SCYNEXIS, Inc. Mr. Machado received a B.A. in German and a B.S. in Economics from Santa Clara University and a J.D. from Harvard Law School.
C. Patrick Machado,从2004年12月开始,他担任公司首席财务官,直到2014年3月,将该职位转换给Mr. Rick Bierly ;从2009年12月到2014年4月他退休期间,他担任首席业务官。之前,从公司2003年9月创立到2004年12月该公司通过合并成为我们公司的全资子公司期间,他在Medivation Neurology担任高级副总裁、首席财务官和董事。从1998年到2001年,他在ProDuct Health公司任职,这是一家私人医疗器材公司,从1998年到2000年,他担任副总裁、首席财务官和总经理;从2000年到2001年他担任高级副总裁和首席财务官。从2001年到2002年,他在Cytyc 公司担任咨询师,帮助该公司收购ProDuct Health 公司的交易事务。他在哈佛大学法学院(Harvard Law School)得到法律博士学位,在圣克拉拉大学(Santa Clara University)得到法语和经济学双学士学位。
C. Patrick Machado was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its chief business officer from 2009 to 2014 and as its chief financial officer from 2004 until his retirement in 2014. From 1998 to 2001 Mr. Machado worked with ProDuct Health, Inc., a medical device company, as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, a diagnostic and medical device company, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado also serves as a member of the board of directors of Arcus Biosciences, Inc., Chimerix, Inc., Turning Point Therapeutics, Inc., Principia Biopharma Inc., and several private companies, and previously served on the board of directors of Endocyte, Inc., Inotek Pharmaceuticals Corporation now Rocket Pharmaceuticals, Inc., Axovant Sciences, Inc. Medivation, Inc. and SCYNEXIS, Inc. Mr. Machado received a B.A. in German and a B.S. in Economics from Santa Clara University and a J.D. from Harvard Law School.